Orales

15:30-15:37

CO-01. CAR-T cells secreting T cell engagers show superior control of leukemia progression than tandem CAR-T cells

Javier Arroyo-Ródenas¹; Laura Díez-Alonso¹; Aida Falgas²; Alba Martínez-Moreno²; Francisco J. Gil-Etayo1; Óscar Aguilar-Sopeña³; Miriam Velasco-Sidro¹; Clara Bravo-Martín³; Ángel Ramírez-Fernández¹; Belén Blanco¹; Pedro Roda-Navarro³; Clara Bueno²; Pablo Menéndez²; Luis Álvarez-Vallina<sup>1

1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain; Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), H12O-CNIO, Madrid, Spain. 2Josep Carreras Leukaemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain. 3Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain</sup>

15:37-15:44

CO-02. Targeting tumour-promoting inflammation in breast cancer by Oncostatin M (OSM) cytokine blockade: implications in immune suppression

Maria Muñoz Caffarel; Peio Azcoaga; Andrea Abaurrea; Sara Manzano; Paloma Petit de Prado; Irati Garmendia; Ander Urruticoechea IIS Biogipuzkoa, Hospital Universitario Donostia, San Sebastián, Guipuzkoa

15:44-15:51

CO-03. Overcoming tumor heterogeneity with dual-targeted STAb-T cells secreting two T cell engagers for the treatment of multiple myeloma

Miriam Velasco-Sidro^1,2,3, Javier Arroyo-Ródenas^1,2,3, Laura Díez-Alonso^1,2,3, Ángel Ramírez-Fernández^1,2,3,§, Luis Álvarez-Vallina<sup>1,2,3

1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain 2Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain 3H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain §Current address: Center for Advanced Cellular Therapies. Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, United States.</sup>

15:51-15:58

CO-04. Next-generation multispecific CAR-T cells: towards a new structured approach for adoptive cell therapies

Alejandro Segura-Tudela; Laura Rubio-Pérez; Ángel Ramírez-Fernández; María Lasa-Lázaro; Luis Álvarez-Vallina Hospital Universitario 12 de Octubre, Madrid, Spain

Poster Session I

Cell-based immunotherapies

15/03/2024 de 10:20-10:50

CP-01 CAR-Ts ARE GETTING VIRAL! UNVEILING A NOVEL APPROACH FOR ALLOGENEIC CAR-T CELL DEVELOPMENT

Mario Vázquez¹; Sergi Betriu¹; Lorena Pérez¹; Natalia Egri²; Europa Azucena González²; Manel Juan²; Hugo Calderón<sup>2

1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 2Hospital Clínic Barcelona, Barcelona, Spain</sup>

CP-02 SIMULTANEOUS CHECKPOINT INHIBITION AND COSTIMULATION ENHANCE ANTI-TUMOR EFFICACY OF BISPECIFIC ANTIBODY-SECRETING T CELLS IN HEMATOLOGICAL AND SOLID TUMORS

Marina Gómez-Rosel^1,2,3; Laura Rubio-Pérez^1,2,3; Belén Blanco<sup>1,2,3

1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain. 2Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. 3Hospital Universitario 12 de Octubre, Madrid, Spain</sup>

CP-03 IMPACT OF THE GASTROINTESTINAL MICROBIOTA ON THE IMMUNE POPULATION OBTAINED DURING THE APHERESIS OF PATIENTS UNDERGOING CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Mireia Uribe-Herranz¹; A. Oliver-Caldés²; E. Rubio³; M. Español-Rego³; N. Martínez-Micaelo⁴; A. Vergara³; O. Yanes⁵; N. Amigó4; M. Montoro²; V. González-Calle⁶; V. Cabañas⁷; B. Martín-Antonio⁸; L. Pérez-Amill⁸; J. L. Reguera⁹; P. Rodríguez-Otero¹⁰; J. M. Moraleda⁷; A. Urbano-Ispizua¹; M. V. Mateos⁶; C. Fernández de Larrea¹; M. Juan<sup>1

1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain. 2Department of Hematology, Institut Clínic de Malalties Hemato-Oncològiques - ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain. 3Department of Microbiology, Hospital Clínic de Barcelona, Barcelona, Spain. 4Biosfer Teslab, Reus, Tarragona, Spain. 5Department of Electronic Engineering, Universitat Rovira i Virgili, Reus, Tarragona, Spain. 6Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Salamanca, Spain. 7Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. 8Fundació Clinic per a la Recerca Biomèdica (FCRB), Hospital Clínic de Barcelona, Barcelona, Spain. 9Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Sevilla, Spain. 10Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC Pamplona, Pamplona, Spain</sup>

CP-04 STAb-T THERAPY FOR MULTIPLE MYELOMA: T LYMPHOCYTES SECRETING T CELL ENGAGERS (STAb-T CELLS) DEMONSTRATE SUPERIOR ANTITUMOR ACTIVITY THAN CAR-T CELLS

Belén Blanco^1,2,3,4, Laura Díez-Alonso^1,2,3, Aïda Falgás^4,5, Javier Arroyo^1,2,3, Marina Gómez-Rosel^1,2,3, Anaïs Jiménez-Reinoso^1,2,3, Paola A. Romecín⁵, Óscar Aguilar-Sopeña^6,7, Ángel Ramírez-Fernández^1,2,3, Alejandro Segura-Tudela^1,2,3, María Jara^8,9,10, Francesc Solé⁵, Antonio Valeri^11,12, Almudena García-Ortiz^11,12, Manel Juan^13,14,15, Joaquín Martínez-López^11,12, Pedro Roda-Navarro^6,7, Beatriz Martín-Antonio¹⁶, Alberto Orfao^8,9,10, Pablo Menéndez^4,5,9,15,17, Clara Bueno^4,5, Luis Ávarez-Vallina^1,2,3,18.

^{1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain. 2Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. 3H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. 4Red Española de Terapias Avanzadas (TERAV), Instituto de Salud Carlos III, Madrid, Spain. 5Josep Carreras Leukaemia Research Institute, Barcelona, Spain. 6Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain. 7Lymphocyte Immunobiology Group, Instituto de Investigacion Sanitaria 12 de Octubre (imas12), Madrid, Spain. 8Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), Universidad de Salamanca. 9Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. 10Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain. 11Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12OCNIO) Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain 12Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. 13Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain. 14 Servei d’Immunologia, Hospital Clinic de Barcelona, Barcelona, Spain. 15Universitat de Barcelona, Barcelona, Spain 16Department of Experimental Hematology, Instituto de Investigación Sanitaria Fundación Jiménez Diaz, (IIS-FJD), UAM, Madrid, Spain. 17Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 18Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain}

CP-05 SELECTIVE EXPANSION OF ANTI-TUMOR NK CELLS AFTER BCG PRIMING AND A PARTICULAR CYTOKINE COMBINATION: NOVEL DONOR-INDEPENDENT CANDIDATES FOR CELL THERAPY

María José Felgueres Planells¹; Gloria Esteso Torneo¹; Álvaro García Jiménez¹; Enrique Vázquez²; Carmen Mestre Durán³; Antonio Pérez Martínez⁴; Hugh T. Reyburn³; Mar Valés Gómez<sup>1

1Centro Nacional de Biotecnología - CNB-CSIC, Madrid, Spain. 2Centro Nacional de Investigaciones Cardiovasculares – CNIC, Madrid, Spain. 3idiPAZ, Madrid, Spain. 4idiPAZ, Universidad Autónoma de Madrid, Madrid, Spain</sup>

CP-06 TUMOR-INFILTRATING LYMPHOCYTE PROFILING: FIRST STEP FOR THE IMPROVEMENT OF TIL BASED THERAPY

Alejandro Ramírez-Chacón¹; Europa Azucena González-Navarro²; Manel Juan<sup>3

1</sup>Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ²Immunotherapy Platform Clínic - Sant Joan de Deu, Barcelona, Spain. ³Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Barcelona, Spain

CP-07 IMMUNOGENICITY ELICITED BY THE ACADEMIC CD19 CHIMERIC ANTIGEN RECEPTOR (ARI-0001) IN RELAPSED/REFRACTORY B-CELL MALIGNANCIES

Ariadna Bartoló-Ibars^1,2,5; Azucena González-Navarro^1,2; Nela Klein-González^1,2,5; Berta Casanovas-Albertí^1,2,5; Valentín Ortiz-Maldonado³; Marta Español-Rego^1,2; Maria Castellà^1,2; Daniel Benítez^1,2; Raquel Cabezón^1,2; Jordi Esteve^3,5,6; Jordi Yagüe^2,5; Mariona Pascal^1,2; Álvaro Urbano-Ispizua^3,5,6; Susana Rives⁴; Julio Delgado^3,5,6; Manel Juan<sup>1,2,5,6

1Plataforma de Inmunoterapia, HSJD-Hospital Clínic Barcelona, Barcelona, España; 2Servicio de Inmunología, CDB, Hospital Clínic, Barcelona, España; 3Servicio de Hematología, ICMHO, Hospital Clínic Barcelona, Barcelona, España; 4Servicio de Hematología, Hospital Sant Joan de Déu (HSJD), Barcelona, España; 5Instituto de Investigaciones Biomédicas August Pi i Sunyer IDIBAPS/FCRB Barcelona, España; 6Universidad de Barcelona, Barcelona, España</sup>

CP-08 CRISPR/Cas9-EDITED CD19-DIRECTED PD-1 DISRUPTED CAR-T CELLS

Blanca Tocornal Garnica¹; Carles Serra Pagès²; Europa Azucena González Navarro²; Manel Juan Otero<sup>2

1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain. 2Department of Immunology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Barcelona, Spain</sup>

Poster Session II

Novel therapeutic targets and strategies

15/03/2024 de 16:45-17:00

CP-09 LYNCH SYNDROME-RELATED NEOANTIGENS PREDICTION AND VALIDATION FOR A DENDRITIC-CELL BASED CANCER PREVENTION VACCINE

Cristina Bayó¹; Giancarlo Castellano²; Teresa Ocaña²; Rebeca Moreira²; Joaquín Castillo²; Maria Pellisé²; Liseth Rivero²; Maria Daca²; Oswaldo Ortiz²; Manel Juan¹; Daniel Benítez-Ribas¹; Francesc Balaguer<sup>2

1Department of Immunology, Immunotherapy Section, Hospital Clínic de Barcelona, Barcelona, Spain. 2Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain</sup>

CP-10 MITOCHONDRIAL PYRUVATE CARRIER 1: TO CANCER CELL METABOLISM AND BEYOND

Ainhoa Ruiz Iglesias¹; Ángel García Aldea¹; Marta Gómez de Cedrón²; Rosa M. Peregil¹; Miguel Ángel Sánchez¹; Emilia Mira¹; Rosa A. Lacalle1; Raquel Blanco¹; Elena Nonnast¹; Teresa Navarro³; María C. Moreno-Ortiz¹; Ana Ramírez de Molina¹; Santos Mañes<sup>2

1Centro Nacional de Biotecnología - CNB-CSIC, Madrid, Spain. 2IMDEA Food Institute (CEI UAM+CSIC), Madrid, Spain. 3Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC/UAM), Madrid, Spain</sup>

CP-11 EPIGENETIC DRUGS TO INDUCE NEUROBLASTOMA SUSCEPTIBILITY TO NKG2D-CAR-T CELLS

Alfonso Navarro-Zapata; Laura Clares-Villa; Carmen Mestre-Durán; Natalia Riestra-Ramos; Marta Ibáñez; Adriana Mañas; Cristina Aguirre-Portolés; Jordi Minguillón; Halin Bareke; Lucía Férnandez; Antonio Pérez-Martínez Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

CP-12 COMBINATION OF mRNA-ENCODED BISPECIFIC ANTIBODIES FOR IMPROVED AND SAFER CANCER IMMUNOTHERAPY

Oana Hangiu¹; Rocío Navarro²; Susana Frago²; Laura Rubio-Pérez¹; Laura Díez¹; Marina Gómez-Rosel¹; Marta Compte²; Luis Álvarez-Vallina<sup>1

1Hospital Universitario 12 de Octubre, Madrid, Spain. 2Leadartis S.L., Madrid, Spain</sup>

CP-13 METABOLIC PRIMING OF LUNG METASTATIC NICHE DRIVES PALMITATE AVAILABILITY AND NF-κB SIGNALING IN BREAST CANCER

Patricia Altea-Manzano^1,2,3; Yawen Li^2,3; Ginevra Doglioni^2,3; Emma Nolan⁴; Juan Fernández-García^2,3; Ilaria Malanchi⁴; Sarah-Maria Fendt<sup>2,3

1Laboratory of Metabolic regulation and Signaling in Cancer, CABIMER-CSIC, Sevilla, Spain. 2Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, VIB, Leuven, Belgium. 3Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium. 4The Francis Crick Institute, London, United Kingdom</sup>

CP-14 PT-112 INDUCES POTENT MITOCHONDRIAL STRESS AND IMMUNOGENIC CELL DEATH IN HUMAN PROSTATE CANCER CELL LINES

Ruth Soler Agesta¹; Raquel Moreno Loshuertos¹; Christina Y. Yim²; Maria T. Congenie²; Tyler D. Ames²; Hannah L. Johnson³; Fabio Stossi³; Joaquín Marco Brualla¹; M. ª Concepción Junquera⁴; Raquel Martínez de Mena⁵; José Antonio Enríquez⁵; Lorenzo Galluzzi⁶; Matthew R. Price²; José Jimeno^1,2; Alberto Anel<sup>1

1Universidad de Zaragoza/Instituto Aragonés de Ciencias de la Salud (IIS-Aragón), Biochemistry and Molecular and Cell Biology, Zaragoza, Spain. 2Promontory Therapeutics Inc., New York, USA. 3Baylor College of Medicine, Integrated Microscopy Core, Houston, Texas, USA. 4Department of Anatomy and Human Histology, Faculty of Medicine, Universidad de Zaragoza/Instituto Aragonés de Ciencias de la Salud (IIS-Aragón), Zaragoza, Spain. 5Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; 6Weill Cornell Medicine, New York, USA</sup>

CP-15 TUMOR PROGRESSION MODIFIES THE EXPRESSION OF VASCULAR LAMININS AND THE IMMUNE LANDSCAPE IN THE SENTINEL LYMPH NODE

Elena Nonnast Fornieles¹; Rosa María Peregil¹; Miguel Ángel Sánchez¹; María del Carmen Moreno-Ortiz¹; Elena Hernández²; Salvador Iborra²; Santos Mañes Brotón¹; Emilia Mira Damaso<sup>1

1Centro Nacional de Biotecnología - CNB-CSIC, Madrid, Spain. 2Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain</sup>

CP-16 ACTIVATION OF DENDRITIC CELLS USING NANOPARTICLES AS AN IMMUNOTHERAPEUTIC STRATEGY FOR THE TREATMENT OF SOLID TUMORS

Jokin Egia¹; Francisco Javier Echanove²; Iker Badiola¹; Patricia García Gallastegi<sup>3

1Department of Cell Biology and Histology, Faculty of Medicine and Dentistry, Universidad del País Vasco, Leioa, Bizkaia, Spain. 2Department of Electricity and Electronics, Faculty of Science and Technology, Universidad del País Vasco, Leioa, Bizkaia, Spain. 3Department of Physiology, Faculty of Medicine and Dentistry, Universidad del País Vasco, Leioa, Bizkaia, Spain</sup>

CP-17 IMPACT OF THE REDUCING AGENT USED IN THE SYNTHESIS OF SILVER NANOPARTICLES ON THE CYTOTOXIC EFFECT ON HEMATOLOGICAL CANCER CELLS

Andrea Carolina Machado-Sulbaran¹; Jovani Guadalupe Aguirre-León²; Saulo Manuel Álvarez-Saldaña³; Trinidad García-Iglesias¹; Belkis Coromoto Sulbaran-Rangel<sup>4

1Instituto de Investigación en Cáncer en la Infancia y Adolescencia (INICIA), Centro Universitario de Ciencias de la salud (CUCS), Universidad de Guadalajara (UDG), Guadalajara, Jalisco, Mexico. 2Doctorate in Pharmacology, Department of Physiology, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara (UDG), Guadalajara, Jalisco, Mexico. 3Bachelor's Degree in Nanotechnology, Centro Universitario de Tonalá (CUTONALA - Centro Universitario de Tonalá), Tonalá, Jalisco, Mexico. 4Department of Water and Energy Studies, Centro Universitario de Tonalá (CUTONALA - Centro Universitario de Tonalá), Tonalá, Jalisco, Mexico</sup>

CP-18 ISOLATION OF CD4+ T CELLS SPECIFIC FOR NY-ESO-1 PRESENTED ON HLA-DRB3*02:02

Berta Casanovas Albertí¹; Andrea Aran¹; Ariadna Bartoló¹; Mariona Pascal²; Europa Azucena González-Navarro²; Manel Juan<sup>2

1Fundació de Recerca Clínic Barcelona (FRCB) - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 2Hospital Clínic de Barcelona, Barcelona, Spain</sup>

Poster Session III

Clinical experiences and biomarkers

16/03/2024

CP-20 ORAL SQUAMOUS CARCINOMA CELLS DIFFERENCIATE MONOCYTES INTO IMMUNOSUPPRESSIVE CD25+CD163+CD206+ MACROPHAGES

Héctor F. Peláez-Prestel; Fernando González Martín; Esther María Lafuente Duarte; Pedro A. Reche Gallardo Department of Immunology, Universidad Complutense de Madrid, Madrid, Spain

CP-21 METHYLATION SIGNATURE OF RESPONSE IN MELANOMA PATIENTS TREATED WITH IMMUNOTHERAPY

Alberto Ríos Muñoz^1,2; Andrea González-Hernández ^1,2; Miguel-Ángel Berciano-Guerrero¹; Jaime Dubbelman^1,3; Beatriz Martínez-Gálvez¹; Ángel Díaz-Lagares³; Isabel Barragán¹; Elisabeth Pérez-Ruiz<sup>1

1Medical Oncology Service (Group of Translational Research in Cancer Immunotherapy and Epigenetics), Regional and Clinical University Hospitals, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain. 2Universidad de Málaga, Málaga, Spain. 3Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Instituto de Investigación Sanitaria de Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS, SERGAS), Santiago de Compostela, Spain</sup>

CP-22 EXOSOMAL microRNAs AS IMMUNOTHERAPY BIOMARKERS: PREDICTING RESPONSE TO PEMBROLIZUMAB IN NON-SMALL CELL LUNG CANCER

Alejandro Castillo Peña; Laura Boyero; Johana Benedetti; Miriam Alonso; Amparo Sánchez-Gastaldo; José Francisco Noguera Uclés; Ana Salinas; M.ª Luisa Valdivia Ferreira; Reyes Bernabé Caro; Sonia Molina Pinelo Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain

CP-23 CHANGES IN INTERFERON-RELATED CYTOKINES DURING PD-(L)1 INHIBITION THERAPY AND THEIR ASSOCIATION WITH IMMUNE-RELATED ADVERSE EVENTS

Leticia Alserawan^1,2; Maria Mulet²; Geòrgia Anguera³; Mariona Riudavets^3,4; Carlos Zamora²; Rubén Osuna²; Jorgina Serra-López³; Andrés Barba Joaquín³; Ivana Sullivan³; Margarita Majem³*; Silvia Vidal²*

^{1Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain. 2Department of Inflammatory Diseases, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IIB Sant Pau), Barcelona, Spain. 3Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 4Department of Pneumologie, Hôpital Cochin - APHP Centre, Paris, France
*These authors contributed equally to this work.}

CP-24 EFFECT OF THE HLA-G/ILT2 PATHWAY AS AN IMMUNE SYSTEM CHECKPOINT IN GASTRIC CANCER

Christian Vaquero-Yuste¹; Óscar Aguilar-Sopeña¹; Inmaculada Lasa²; Adela López²; Remedios Gómez²; Alberto Gutiérrez-Calvo²; Pedro Roda-Navarro^1,3; José Manuel Martin-Villa^1,4; Ignacio Juárez<sup>1

1Department of Immunology, Ophthalmology, and Otorhinolaryngology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. 2Department of General and Digestive Surgery, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. 3Lymphocyte Immunobiology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain. 4Department of Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain</sup>

CP-26 ASSOCIATION OF PDE4D AND STK11 AS BIOMARKERS OF THE RESPONSE TO IMMUNOTHERAPY IN NOT SMALL CELLS LUNG CARCINOMA (NSCLC)

Laura Boyero¹; María G. Velasco-Domínguez¹; Sofía Boyero-Corral¹; José Francisco Noguera-Uclés¹; Miriam Alonso²; Amparo Sánchez-Gastaldo²; Johana Cristina Benedetti²; Sonia Molina-Pinelo¹; Reyes Bernabé Caro<sup>2

1 Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain. 2Hospital Universitario Virgen del Rocío, Sevilla, Spain</sup>

CP-27 IMPACT OF CYCLIN INHIBITORS (CDK4/6I) ON IMMUNE CELL POPULATIONS IN FIRST-LINE TREATED METASTATIC BREAST CANCER PATIENTS

María Luisa Sánchez León; Carlos Jiménez Cortegana; Fernando Henao Carrasco; Natalia Palazón Carrión; Silvia Silva Romeiro; Víctor Sánchez Margalet; Luis de la Cruz Merino Hospital Universitario Virgen Macarena, Sevilla, Spain

CP-28 OVERCOMING IMMUNOTHERAPY RESISTANCE: THE INVERSION OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE KEY TO TREATMENT SUCCESS

Lucas Sanz Monge¹; Javier Plou Izquierdo²; Javier Garrido Gallego¹; Tomás Cunquero Tomás³; Alfonso Berrocal Jaime<sup>1

1Hospital General Universitario de Valencia, Valencia, Spain. 2CIC nanoGUNE, Donostia, Guipuzkoa, Spain. 3Hospital General de Requena, Requena, Valencia</sup>

CP-29 CD8+ NKs AS A POTENTIAL BIOMARKER OF COMPLETE RESPONSE AND SURVIVAL WITH LENALIDOMIDE PLUS R-GDP IN THE R2-GDP-GOTEL TRIAL IN RECURRENT/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Lourdes Hontecillas Prieto¹; Daniel J. García-Domínguez²; Víctor Sánchez-Margalet²; Luis de la Cruz-Merino<sup>3

1Clinical Biochemistry Service, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain. 2Department of Medical Biochemistry and Molecular Biology and Immunology, School of Medicine, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain. 3Hospital Universitario Virgen Macarena, Sevilla, Spain</sup>

CP-30 EXPERIENCE IN A TERTIARY HOSPITAL ON IMMUNE-MEDIATED HYPOPHYSITIS SECONDARY TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

Paula Gutiérrez Méndez; Pablo Jara Martín; Ignacio José Durán Martínez; Carlos García-Mochales Fortún; Juan Diego Cacho Lavín; Marta Sotelo García; Clara Castro Carballeira; María Ibáñez Alda; Amaia Saiz Herrero; María Isabel Domínguez Rullán; María Isabel Svetli Pérez; Almudena García Castaño Hospital Universitario Marqués de Valdecilla, Santander, Spain

CP-31 IMMUNO REVOLUTION ERA: TRANSFORMING SURVIVAL IN ADVANCED LUNG CANCER, CREATING LONG SURVIVORS’ PATIENTS

Teresa Robles Bermejo; Elisabeth Aguilar Jiménez; Xabier Mielgo Rubio; Mónica Esteban García; Yanelis Pernas Sánchez; Rocío Avilés Peña; Susana Hernando Polo; Alicia Hurtado Nuño; Clara Olier Garate; Diana Moreno Muñoz; Juan Carlos Cámara Vicario; Araceli Rodríguez Morales Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

CP-32 EXPLORATORY ANALYSIS OF LIPI SCORE IN A SMALL CELL LUNG CANCER COHORT, DISCERNING PROGNOSTIC FROM PREDICTIVE POTENTIAL RELEVANCE AS A CLINICAL BIOMARKER

Mónica Esteban García; Xabier Mielgo Rubio; Elisabeth Jiménez Aguilar; Teresa Robles Bermejo; Yanelis Pernas Sánchez; Rocío Avilés Peña; Susana Hernando Polo; Clara Olier Garate; Diana Moreno Muñoz; Elia Pérez Fernández; Araceli Rodríguez Morales; Juan Carlos Camara Vicario Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain Hospital Universitario Fundación Alcorcón

CP-33 CHECKPOINTS INHIBITORS IN A RARE THYMOMA-ASSOCIATED IMMUNODEFICIENCY

Miriam Velasco-Sidro¹; Luis Andara-Cordero²; Estela Paz-Artal²; Óscar Cabrera-Marante<sup>2

1Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain. 2Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain. 3Hospital Universitario 12 de Octubre, Madrid, Spain</sup>